Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncodesign Signs a Partnership Agreement with Sanofi

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Oncodesign will apply its Nanocyclix® technology to one of Sanofi's kinase targets.

Oncodesign has announced that it has signed a second research collaboration agreement with Sanofi.

This partnership follows a first agreement signed in summer 2012, relating to a number of kinase targets being developed by Sanofi. This second agreement aims to identify inhibitors of a kinase which plays a key role in tissue protection and repair.

Oncodesign will use its Nanocyclix® technology to design and synthesize potent new selective inhibitors. Sanofi will have exclusive licensing rights to the molecules that result from the collaboration.

Nanocyclix is a proprietary medicinal chemistry technology and a research platform based on a chemical macrocyclization process.

The kinase inhibitors obtained using this process are potent and highly selective, because their structures demonstrate exceptional shape complementarity with the binding site of the kinase ATP (adenosine triphosphate).

The resulting selectivity is unparalleled, especially for kinases that are highly homologous. Drawing on proven expertise, the technology also allows the pharmacokinetic properties of Nanocyclix compounds to be enhanced at an increased rate.

Oncodesign leads the field in macrocyclic kinase inhibitors, offering partnership opportunities based on its own research programs and partners' programs that target the kinases to which the Nanocyclix technology is applied.

“This new agreement with Sanofi demonstrates the level of interest in our Nanocyclix technology from some of the most well-renowned pharma companies. This is our third collaboration agreement in a year of drug discovery, establishing our company as a leader in the field of kinase inhibitors in a variety of therapeutic areas,” says Dr Philippe Genne, chairman, CEO and founder of Oncodesign.

Under the terms of the agreement, Oncodesign will apply its Nanocyclix technology to a key target implicated in the therapeutic area of tissue protection and repair.

The cost of the initial phase of the work is to be met in full by Sanofi, who will have exclusive rights to the results of the program. The financial details have not been disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and UCB Enter into a Research Collaboration
The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Thursday, November 14, 2013
Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.
Tuesday, September 10, 2013
Oncodesign Signs Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.
Thursday, March 28, 2013
Oncodesign and OSEO Announce Funding of EUR 13.4 Million
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.
Tuesday, March 12, 2013
Oncodesign and the LNGT Enter into a Research Collaboration
Collaboration to advance Oncodesign's Parkinson’s disease program towards clinical development.
Wednesday, December 19, 2012
Oncodesign Enters into a Research Collaboration and License Agreement with Sanofi
Collaboration for the application of Oncodesign’s Nanocyclix® technology to Sanofi’s kinase targets.
Saturday, September 15, 2012
Oncodesign and Ipsen Enter into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix(R) Technology for next generation kinase inhibitors and Ipsen’s expertise in Movement Disorders.
Thursday, January 05, 2012
Oncodesign and Ipsen Enter Into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix® technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Thursday, January 05, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!